利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

26 条记录 (耗时 0.046 秒)

    NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS
    2.
    发明申请
    NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS 审中-公开
    非基因麦芽宁浓度HORMONE受体-1拮抗剂和方法

    公开(公告)号：US20090011994A1

    公开(公告)日：2009-01-08

    申请号：US12141228

    申请日：2008-06-18

    申请人： Philip D. Stein ,  Sharon N. Bisaha ,  Saleen Ahmad ,  Khehyong Ngu ,  William N. Washburn

    发明人： Philip D. Stein ,  Sharon N. Bisaha ,  Saleen Ahmad ,  Khehyong Ngu ,  William N. Washburn

    IPC分类号： A61K38/22 ,  A61K31/4965 ,  C07D241/18 ,  A61K31/497 ,  A61P3/04 ,  A61P3/10 ,  A61K31/60 ,  C07D401/04 ,  A61K31/675

    CPC分类号： C07D241/18 ,  C07D401/12

    摘要： The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R1, R2, R3, R8, and R9 are defined herein.Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

    摘要翻译： 本申请提供化合物，包括其中R 1，R 2，R 3，R 8和R 9在本文中定义的根据式I的所有立体异构体，溶剂合物，前药和药学上可接受的形式。 另外，本申请提供含有至少一种根据式I的化合物和任选的至少一种另外的治疗剂的药物组合物。 最后，本申请提供了通过施用治疗有效剂量的根据式I的化合物治疗患有MCHR-1调节的疾病或病症例如肥胖，糖尿病，抑郁或焦虑的患者的方法。

    Substituted pyrazinone melanin concentrating hormone receptor-1 antagonists and methods
    3.
    发明授权
    Substituted pyrazinone melanin concentrating hormone receptor-1 antagonists and methods 有权
    取代的吡嗪酮黑色素浓缩激素受体-1拮抗剂和方法

    公开(公告)号：US08067420B2

    公开(公告)日：2011-11-29

    申请号：US13028570

    申请日：2011-02-16

    申请人： Philip D. Stein ,  Sharon N. Bisaha ,  Saleem Ahmad ,  Khehyong Ngu ,  William N. Washburn

    发明人： Philip D. Stein ,  Sharon N. Bisaha ,  Saleem Ahmad ,  Khehyong Ngu ,  William N. Washburn

    IPC分类号： A61K31/4965

    CPC分类号： C07D241/18 ,  C07D401/12

    摘要： The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R1, R2, R3, R8, and R9 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

    摘要翻译： 本申请提供化合物，包括其中R 1，R 2，R 3，R 8和R 9在本文中定义的根据式I的所有立体异构体，溶剂合物，前药和药学上可接受的形式。 另外，本申请提供含有至少一种根据式I的化合物和任选的至少一种另外的治疗剂的药物组合物。 最后，本申请提供了通过施用治疗有效剂量的根据式I的化合物治疗患有MCHR-1调节的疾病或病症例如肥胖，糖尿病，抑郁或焦虑的患者的方法。

    Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
    8.
    发明授权
    Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists 有权
    取代的噻吩并[3,2-D]嘧啶作为非碱性黑色素浓缩激素受体-1拮抗剂

    公开(公告)号：US07745447B2

    公开(公告)日：2010-06-29

    申请号：US11586147

    申请日：2006-10-25

    申请人： William N. Washburn ,  Saleem Ahmad ,  Khehyong Ngu

    发明人： William N. Washburn ,  Saleem Ahmad ,  Khehyong Ngu

    IPC分类号： C07D495/04 ,  A61K31/519 ,  A61P25/22 ,  A61P3/04 ,  A61P3/10

    CPC分类号： C07D495/04

    摘要： The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

    摘要翻译： 本申请提供化合物，包括根据式I的所有立体异构体，溶剂合物，前药和药学上可接受的形式。另外，本申请提供含有至少一种根据式I的化合物和任选的至少一种另外的治疗剂的药物组合物。 最后，本申请提供了通过施用治疗有效剂量的根据式I的化合物治疗患有MCHR-1调节的疾病或病症例如肥胖，糖尿病，抑郁或焦虑的患者的方法。